All In Biotech

Investigational drug · Phase 2

MHB034C

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignant Solid Tumor.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "MHB034C"

First trial start

2026

Dec 20, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MHB034C", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Malignant Solid Tumor

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "MHB034C" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Malignant Solid Tumor

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

  • SCTB41Phase 36 trials

    Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor

  • PRL3-ZUMABPhase 34 trials

    Intra-IMMUSG Pte Ltd · Advanced Malignant Solid Tumor, Solid Tumor, Advanced Solid Cancers

  • MHB039APhase 24 trials

    Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer

  • MHB036CPhase 23 trials

    Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Breast Cancer, Advanced Malignant Solid Tumor, Advanced Lung Cancer

  • Recombinant Human IL1215-PDL1B Oncolytic HSV-1, VG161Phase 23 trials

    CNBG-Virogin Biotech (Shanghai) Ltd. · Advanced Malignant Solid Tumor, Sarcoma, Advanced Intrahepatic Cholangiocarcinoma

  • Suzhou BlueHorse Therapeutics Co., Ltd. · Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor

  • SCTB39-1Phase 22 trials

    Sinocelltech Ltd. · Advanced Malignant Solid Tumor

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.